WP
ABBV icon

WealthSource Partners’s AbbVie ABBV Stock Holding History

WealthSource Partners’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		$928K Buy
5,986
+43
+0.7% +$6.27K 0.06% 212
2023
Q3 		$886K Sell
5,943
-98
-2% -$14.4K 0.06% 208
2023
Q2 		$814K Sell
6,041
-446
-7% -$65.4K 0.05% 224
2023
Q1 		$1.03M Buy
6,487
+17
+0.3% +$2.6K 0.07% 195
2022
Q4 		$1.05M Sell
6,470
-425
-6% -$65.2K 0.07% 188
2022
Q3 		$925K Sell
6,895
-7
-0.1% -$1K 0.07% 206
2022
Q2 		$1.06M Sell
6,902
-1,902
-22% -$291K 0.08% 183
2022
Q1 		$1.43M Sell
8,804
-655
-7% -$95.1K 0.1% 165
2021
Q4 		$1.28M Sell
9,459
-193
-2% -$22.8K 0.1% 154
2021
Q3 		$1.04M Sell
9,652
-3,066
-24% -$350K 0.09% 168
2021
Q2 		$1.43M Buy
12,718
+657
+5% +$74K 0.13% 127
2021
Q1 		$1.3M Buy
12,061
+1,269
+12% +$136K 0.13% 122
2020
Q4 		$1.16M Buy
10,792
+3,644
+51% +$350K 0.13% 107
2020
Q3 		$626K Buy
7,148
+1,036
+17% +$97.5K 0.08% 159
2020
Q2 		$600K Buy
6,112
+31
+0.5% +$2.73K 0.09% 164
2020
Q1 		$463K Buy
6,081
+242
+4% +$20.6K 0.07% 183
2019
Q4 		$517K Sell
5,839
-4,198
-42% -$349K 0.07% 224
2019
Q3 		$760K Sell
10,037
-856
-8% -$58.7K 0.11% 179
2019
Q2 		$792K Buy
10,893
+4,310
+65% +$339K 0.12% 172
2019
Q1 		$530K Sell
6,583
-873
-12% -$71.4K 0.12% 159
2018
Q4 		$687K Buy
7,456
+763
+11% +$67.1K 0.2% 115
2018
Q3 		$633K Sell
6,693
-228
-3% -$21.6K 0.17% 128
2018
Q2 		$641K Buy
6,921
+1,826
+36% +$178K 0.18% 123
2018
Q1 		$482K Buy
5,095
+1,260
+33% +$138K 0.15% 147
2017
Q4 		$371K Sell
3,835
-941
-20% -$88.7K 0.11% 173
2017
Q3 		$424K Buy
4,776
+51
+1% +$3.88K 0.14% 159
2017
Q2 		$343K Buy
4,725
+533
+13% +$35.8K 0.12% 181
2017
Q1 		$273K Buy
+4,192
New +$264K 0.1% 212
2016
Q3 		– Sell
-4,303
Closed -$266K – 260
2016
Q2 		$266K Sell
4,303
-4,867
-53% -$297K 0.1% 189
2016
Q1 		$524K Buy
+9,170
New +$511K 0.21% 92

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

WealthSource Partners's ABBV Position: Q4 2023 in Review

WealthSource Partners increased its AbbVie (ABBV) stake by 0.72% in Q4 2023, buying an estimated $6.27K and bringing the position to 5,986 shares worth $928K. The position accounts for 0.06% of the portfolio, ranked #212.

WealthSource Partners first reported a position in ABBV in Q1 2016 and has held it in 30 quarters since. The position peaked at $1.43M in Q2 2021. 3,323 funds tracked by Wall St. Rank hold ABBV as of Q4 2023.

  • WealthSource Partners held 5,986 shares of AbbVie worth $928K as of Q4 2023.
  • WealthSource Partners bought 43 AbbVie shares in Q4 2023, an estimated $6.27K.
  • AbbVie made up 0.06% of WealthSource Partners's portfolio in Q4 2023, its #212 holding.
  • WealthSource Partners first reported a position in AbbVie in Q1 2016 and has held it in 30 quarters since.
  • WealthSource Partners's AbbVie position peaked at $1.43M in Q2 2021.
  • 3,323 funds tracked by Wall St. Rank held AbbVie as of Q4 2023.

Based on WealthSource Partners's 13F filing for Q4 2023, filed 16 Jan 2024.